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ABSTRACT
The interaction of the antiestrogen tamoxifen (Tx) with calmodulin(CaM) was investigated by cross-linking between the protein and |3H|
tamoxifen aziridine. We observed that CaM binds Tx in a Ca2+-dependent
manner and that two components are involved in the binding, with
apparent dissociation constants (A'(l)of about 6 u\i and 9 MM-The high
affinity binding site has a maximal capacity of 25 pmol/mg protein,
whereas the low affinity binding site has a />'â€žâ€ž,,value of 120 nmol/mg
protein. The stimulatory effect of ( Â¡r*is maximal at the pCa value of 5,
and it is noncompetitively inhibited by Mg2+. In the micromolar range,
the cation-dependent interaction of Tx with CaM exhibits positive coop-
erativity (nn- 1.4) and it is specific in the sense that it is inhibited by
unlabeled Tx and by the CaM antagonist trifluoperazine. In contrast, no
specificity was observed for the Tx binding, which is cation independent.
Tx in the nanomolar range forms complexes with CaM which can be
visualized by fluorography after electrophoretic separation in a polyacryl-
amide gel. Furthermore, CaM antagonism of Tx was observed with
respect to inhibition of the CaM effect on the RBC membrane (Ca2* +
Mg2+)-ATPase. The results indicate that Tx may alter Ca2+-dependent
processes by interacting directly with CaM.
INTRODUCTION
Tx,3 a synthetic nonsteroidal antiestrogen, has been success
fully used in the therapy of human breast cancer (1-3). How
ever, the mechanism by which Tx inhibits mammary cancer cell
proliferation is not well understood. It has been suggested that
Tx antagonizes the growth-enhancing activity of estradiol by
competing with the hormone for binding to estrogen receptors
(4-7). However, it has been reported that antiestrogen binding
sites, distinct from the estrogen receptors, exist in the cell and
bind Tx with high affinity (8-13). Furthermore, some of the
biological effects of Tx are not reversed by estrogen (6, 14),
which indicates that Tx acts on target molecules other than the
estrogen receptor.
CaM, which is a regulatory protein of many cellular processes
dependent on Ca2+, has been suggested as a good candidate for
mediating estrogen-independent processes involved in cell pro
liferation (15-17). Indeed, some authors reported that Tx in
hibits the activation of cAMP phosphodiesterase by CaM
through a process similar to that of the phenothiazines (16,
18). It has been suggested that the structural similarities be
tween triphenylethylene antiestrogens and phenothiazines form
the basis for the CaM antagonism of Tx, since both types of
drugs contain an hydrophobic region of aromatic rings and an
hydrophilic cationic alkyl amino side chain (19, 20), which
interact with the CaM domain exposed in the presence of Ca2+
(21). These observations support the idea that Tx may interact
directly with CaM. However, a detailed analysis of this inter
action has not yet been reported.
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In this work, we studied the characteristics of Tx binding to
CaM isolated from bovine brain and we investigated the involve
ment of the Tx-CaM complex in the inhibition of the CaM-
modulated (Ca2+ + Mg2+)-ATPase of the RBC membrane.
MATERIALS AND METHODS
Materials. ['H]Tamoxifen aziridine (26 Ci/mmol), nonradiolabeled
tamoxifen, and Amplify were purchased from Amersham (London,
England); dextran T70 from Pharmacia (Uppsala, Sweden); /V,/V-di-
methylformamide from Merck (Darmstadt, Germany); charcoal from
Norit, monothioglycerol, and /V-tris[hydroxymethyl]-2-amino-ethane
sulfonic acid from Sigma (St. Louis, MO).
Binding of |'H|TAZ to CaM Isolated from Bovine Brain. CaM was
isolated from bovine brain cortex as described by Alface and Pires (22).
The purified CaM (10-20 Mg)was incubated 3 h, at 25Â°C,in a medium
containing 10 mM iV-tris[hydroxymethyl]-2-aminoethane sulfonic acid
(pH 7.0), 12 mM monothioglycerol, 250 mivi sucrose, 5-25 nM [3H]
TAZ, 5 HIMEDTA (if present), 0.5 mM CaCl2 or 5 ITIMMgCl2 or CaCl2
plus MgCI2 (0.5 mw plus 5 mM), in a total volume of 200 /Â¿I.Aliquots
of 50 /jl of charcoal-dextran suspension (2.5% charcoal Norit A and
0.25% dextran T70 in 10 mM A'-tris[hydroxymethyl]-2-aminoethane
sulfonic acid, pH 7.0, 12 HIMmonothioglycerol, 250 mM sucrose) were
added to each sample. The tubes were then transferred to an ice-water
bath and kept for 15 min with occasional vortexing. Then, the tubes
were centrifuged 10 min at 10,000 rpm in an Eppendorf microfuge.
Finally, the radioactivity was measured in 150 M' of the supernatant
fluid.
Some experiments were carried out in the presence of different Ca2+
concentrations adjusted with 1 mM ethylene glycol bisfA^W-tetraacetic
acid).
The optimal concentrations of CaM and ['HjTAZ, as well as the
optimal temperature and incubation time, were tested to achieve max
imal (Ca2+ + Mg2+)-dependent binding.
Following the precautions of Katzenellenbogen et al. (23). [3H]TAZ
was diluted from the stock (in ethanol) into dimethylformamide just
before the experiment. Then, it was added directly to the incubation
medium to yield a final concentration of 5-8 nM [3H]TAZ and about
5% dimethylformamide.
In the experiments using micromolar concentrations of Tx, we used
8 nM [3H]TAZ and we added unlabeled Tx to obtain the desired Tx
concentration in the reaction medium.
Assay of Competition between |3H)TAZ and Nonradioactive Tx or
Trifluoperazine for Tx Binding Sites of CaM. CaM ( 10 /Â¿g)was incubated
with 8 nM |'H]TAZ, at 25Â°Cfor 1 h, in the presence of CaCI2 (0.5 mM),
MgCl2 (5 mM), and nonradioactive Tx or trifluoperazine (0.1-260 MM).
Bound and unbound ligand were separated by the DCC technique
described above, and the radioactivity was counted in the resulting
supernatant.
Fluorography of CaM Labeled with |3H|TAZ. CaM (100 Mg) was
incubated 3 h, at 25Â°C,with [3H]TAZ (40 nM) in the presence or
absence of cations. The assay was performed in the same experimental
conditions as described above. The unbound [3H]TAZ was removed by
the DCC technique and about 60 MBof the CaM, contained in the
supernatant, were electrophoresed in a 10% Laemmli one-dimension
slab gel (24). The gel was stained with Coomassie blue, soaked in
Amplify 30 min in the dark, and dried in a gel slab drier (Pharmacia,
model GSD-4). Then, it was fluorographed at -80Â°Cusing a Du Pont
Cronex 2D X-ray film.
Assay of ATPase Activity. CaM-depleted RBC plasma membrane
was isolated by the method of Buckley (25).
The (Ca2+ + Mg2*)-ATPase activity was measured at 25Â°Cin a
medium containing 2 mM Tris, 40 mM KCI, 20 mM NaCl, 50 MMCaCl2,
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and 3 HIMMgCl2, at pH 7.2. To 183 ^1 of this buffer were added 15 n\
of CaM solution (10 Â¿jg),5 n\ of different concentrations of Tx in
dimethylformamide, and 50 /il of the RBC ghost suspension (250 Mgof
protein). The reaction was started by adding 2 mvi ATP. The ATP
hydrolysis was determined by measuring the continuous release of H*
for 10-15 min, as previously described (26, 27). In some experiments,
(Ca2* + Mg2*)-ATPase purified by CaM-affinity chromatography was
used instead of native membranes.
Control experiments were performed to measure the effect of di
methylformamide in the CaM-stimulated Ca2*-ATPase activity.
RESULTS
Binding of |3H|TAZ to CaM. Tx binds to CaM in a cation-
dependent manner. Fig. 1 shows that Ca2* has a strong stimu
latory effect on the binding of [-'H]TAZ to CaM. At 5 nivi Tx,
CaM binds about 21 pmol of [3H]TAZ/mg of CaM in the
presence of Ca2+, whereas only 7 pmol of drug are bound in the
absence of cations (EDTA present). Added Mg2+ has a slight
stimulatory effect on the ['H]TAZ binding by CaM (=11 pmol/
mg CaM), but it reduces the Ca2+ effect from 21 to 18 pmol
[3H]TAZ/mg CaM when both cations are simultaneously added
to the reaction medium. The effect is in agreement with the
results depicted in Fig. 2, where it is evident that Mg2+ reduces
the ['HJTAZ binding of CaM, even at high Ca2* concentrations.
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Fig. 1. Effect of divalent cations on the binding of ['HJTAZ to purified CaM.
CaM (1011%)was incubated with 5 n\i [3H]TAZ in the presence of Ca2* (0.5 HIM).
MgClÂ¡plus Cad, (0.5 mm plus 5 mM). MgCI2 (5 HIM),or EDTA (5 mivi) in a
medium containing 10 mM A'-tris[hydroxymethyl]-2-aminoethane sulfonic acid.
pH 7.0, 250 mM sucrose, and 12 mM monothioglycerol. The unbound [3H|TAZ
was removed by the DCC technique, as described in "Materials and Methods."
The radioactivity was counted in the resulting supernatant, and ihe amount of
bound |3H]TAZ was expressed per mg of protein. D, cation-independent binding
of |JH]TAZ to CaM; E3,cation-dependent binding of |3H]TAZ to CaM.
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Fig. 2. Effect of pCa on the interaction of [3H|TAZ with CaM. CaM (10 jig)
was incubated in the presence or absence of Mg!* (5 mM) with [3H|TAZ (5 nM).
at different free calcium concentrations (pCa values between 7 and 3). as describedin "Materials and Methods." â€¢.presence of Mg2*; O, absence of Mg2*.
Above IO'5 M Ca2+, about 22 pmol ['H]TAZ/mg CaM are
bound to CaM in the absence of Mg2+, whereas in its presence
the [3H]TAZ binding to CaM is about 18 pmol/mg CaM.
The stimulatory effect of Ca2* increases as the Ca2* concen
tration in the medium increases, reaching a maximal value at
about 10~5 M (pCa = 5) (Fig. 2). It appears that the optimal
pCa value for the [-'HJTAZ binding to CaM is not altered by
the presence of Mg2*, suggesting that Mg2* acts by a mechanism
other than simple competition.
The Ca2*-dependent binding of Tx to CaM is observed at
concentrations of Tx as low as 5-25 nM and it is saturable (Fig.
3, left), with a KAof about 6 nM and a B mai of 25 pmol/mg
CaM (Fig. 3, right). On the other hand, we found that, in the
micromolar range of Tx concentrations, there is another class
of Ca2*-dependent binding sites with a Kd of about 10 ÃŸMand
a B maxof 120 nmol/mg CaM (Fig. 4). The second component
of the graph represents nonspecific Tx binding, which is Ca2*
independent. We observed that, at concentrations above 80 Â¿Â¿M,
no significant difference exists between Tx binding (=175
nmol/mg CaM) in the presence or absence of Ca2* (Fig. 4). It
appears that Ca2*-independent binding continuously increases
as Tx concentration in the medium increases, whereas Ca2*-
dependent binding saturates and is masked by the Ca2+-inde-
pendent component at high Tx concentrations (Fig. 4). We also
observed that, in the micromolar range Tx concentrations, the
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Fig. 3. Characterization of high affinity Tx binding to CaM. CaM (20 jig) wasincubated with various concentrations of ['H|TAZ in the presence of Ca2* (0.5
mM) or EDTA (5 mM) in a buffer solution, as described in Fig. I. The bound and
unbound Tx were separated by the DCC technique, as described in "Materials
and Methods." Left, saturation curve; right, Scatchard analysis. O, total binding:
A, Ca2*-dependent binding; â€¢,Ca2*-independent binding. The Ca!*-dependent
binding was obtained by subtracting the Ca2*-independent binding from the total
binding.
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Fig. 4. Characterization of low affinity Ca2*-dependent binding of Tx to CaM.
CaM (20 fig) was incubated with various concentrations (0.5-80 ^M) of Tx in the
presence of Ca2* plus Mg2* (0.5 HIMplus 5 mM) or EDTA (5 mM), in a buffer
solution containing 8 nM [3HJTAZ and the components described in Fig. 1. O,
Tx binding in the presence of Ca2*; â€¢,Tx binding in the presence of EDTA.
Inset, Scatchard plot of the same data. Only those points where 8 /JM < [Tx] <
25 JIMwere used in the determination of B mâ€ž.
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Ca2*-dependent binding of Tx to CaM is cooperative, with an
Hill coefficient of 1.4 (Fig. 5), in agreement with the irregular
Scatchard analysis observed between 0.5 and 7 fiM Tx (Fig. 4,
inset). Furthermore, we found that the Ca2*-dependent binding
of Tx to CaM is specific, as judged by the competition studies
depicted in Fig. 6. It is shown that unlabeled Tx or trifluoper-
azine reduces the amount of [3H]TAZ bound to CaM in a Ca2*-
dependent manner but the inhibition occurs only above 7 MM
concentrations of the unlabeled drugs. Below this concentration
there is no drug competition, since cooperative effects occur
(Fig. 6), in agreement with the observation of Fig. 4, inset. In
contrast, Tx binding was not decreased by the competitors
when the assay was performed in the absence of cations. It
appears, therefore, that Ca2+-dependent Tx binding is CaM
specific, whereas Ca2*-independent binding is nonspecific in
the sense that it cannot be displaced by an excess of Tx or
trifluoperazine.
The IC50values found for Tx and trifluoperazine competition
were about 40 Â¿IM(Fig. 6A) and 50 MM(Fig- 6S), respectively,
which indicates that, in the micromolar range, Tx and trifluo
perazine are similarly bound to CaM.
Fluorography of CaM Labeled with [3H]TAZ. The effect of
cations on the interaction of Tx with purified CaM can be
visualized by fluorography after gel electrophoresis of CaM
previously cross-linked with [3H]TAZ (Fig. 7). Under these
conditions, only covalently bound [3H]TAZ remains bound to
CaM. The nonspecific binding of Tx to CaM is disrupted by
urea (8 M)-containing buffer before the electrophoresis, so that
it is not visualized in the gel.
In the presence of Ca2*, CaM appears strongly labeled by
-1
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Fig. 5. Hill plot analysis of Tx binding to CaM. The plot was performed with
the results (Ca:*-dependent binding) depicted in Fig. 4.
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Fig. 6. Competition between [3HJTAZ and nonradiolabeled Tx or trifluoper
azine for Ca2*-dependent Tx binding sites of CaM. CaM (15 jjg) was incubated I
h at 25Â°Cwith various concentrations (0.1-260 Â»JM)of Tx or trifluopcrazine, in
a medium containing Ca2* plus Mg2* (0.1 mM plus 5 mM) or EDTA (5 mM) and
8 n.M ['H| I \/. in a buffer solution as described in Fig. 1. The unbound ligands
were removed by the DCC technique as described in "Materials and Methods."
Left, competition between [3H]TAZ and unbound Tx; right, competition between
[3H]TAZ and trifluoperazine. O, presence of Ca2*, â€¢.absence of cations (EDTA
present).
[3H]TAZ (Fig. IB, lanes 1 and 2), whereas, in the absence of
cations (EDTA present), no labeling is observed (Fig. IB, lane
4). In contrast to the strong stimulatory effect of Ca2*, Mg2*
promotes a negligible interaction between CaM and[3H]TAZ (Fig. IB, lane 3). As a control (Fig. 7'A), we observed
that neither treatment of CaM with [3H]TAZ (Fig. 1A, lane 1,
2, 3, and 4) nor treatment with DCC, used to remove unbound[3H]TAZ (Fig. 1A, lane 5), alters the normal electrophoretic
mobility or the amount of CaM recovered in the gel (Fig. 7/4,
lane 6).
Effect of Tx and Trifluoperazine on the (Ca2* + Mg2+)-ATPase
Activity of RBC Membranes. RBC membranes, previously de
pleted of endogenous CaM by treatment with EDTA, exhibit
an ATPase activity which is significantly stimulated by addition
of exogenous CaM. Fig. 8 shows that concentrations of Tx up
to 50 MMinhibit the stimulatory effect of CaM on the ATPase
(40 nmol of ATP hydrolyzed/mg of protein), whereas the basal
ATPase, measured in the absence of CaM, is not affected.
The IC50 value (~15 MM)obtained for Tx inhibition of the
ATPase is similar to that (=18 MM)obtained for trifluoperazine
inhibition of the enzyme (Fig. 8), which indicates that, in the
micromolar range, both drugs have similar CaM antagonism,
in agreement with the observations depicted in Fig. 6.
We also observed that the inhibitory effect of Tx on the RBC
membrane (Ca2* + Mg2*)-ATPase activity can be reversed by
adding an excess of CaM (Fig. 9). At about 30 MMTx, the (Ca2*
+ Mg2*)-ATPase activity was recovered from about 40 to 60
nmol ATP hydrolyzed/mg protein/min by adding 80 Mgexcess
of endogenous CaM. This observation suggests that the effect
of Tx is probably mediated by CaM rather than by a direct
effect on the enzyme. Interestingly, we observed that, using
purified (Ca2* + Mg2*)-ATPase, the CaM stimulation of the
enzyme is inhibited by 50 nM Tx (results not shown), which
indicates that CaM inactivation occurs in the nanomolar range
of Tx concentrations. Presumably, when native membranes are
used, most of the Tx added (micromolar range) is bound to
membrane lipids, so that the actual free Tx concentration
available to the Tx target molecule (CaM) is less than expected.
The results indicate that CaM has two classes of Ca2*-
dependent binding sites for Tx and that it is functionally inac
tivated by interaction with the antiestrogen drug.
DISCUSSION
The binding of Tx to CaM isolated from bovine brain was
studied by cross-linking between [3H]TAZ and the protein.
[3H]TAZ behaves as Tx except that it is irreversibly bound,
whereas Tx binding is reversible (23, 28). We observed that the
interaction of Tx with CaM is influenced by Ca2* and Mg2*.
Ca2* and Mg2* increase the binding of the drug to CaM, but
the stimulatory effect of Ca2* is more potent than that of Mg2*
(Fig. 1). When both cations are present in the medium, we
found that Mg2* reduces the stimulation by Ca2*, but the effect
is not due to simple competition between these cations. Indeed,
we observed the same amplitude of the Mg2* effect even at high
concentrations of Ca2* in the reaction medium (Fig. 2). It
appears that Mg2* modifies the Ca2*-dependent CaM confor
mations, so that it is differently recognized by several ligands.
Thus, whereas Mg2* inhibits the Ca2*-dependent binding of the
CaM antagonist Tx, it enhances the binding of CaM to its
receptors in various types of biomembranes (29-31). These
observations are supported by those of Tanokura and Yamada(32), who suggested that the overall structure of the Ca2*-CaM
complex is loosened in the presence of Mg2* and tightened in
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Fig. 7. Interaction of [3H|TAZ with CaM. CaM (100 jig) was incubated 3 h at 25Â°Cwith |JH]TAZ (40 nin) in the presence or absence of cations, as described in
"Materials and Methods." The unbound |'H]TAZ was removed by the DCC technique and about 60 /jg of the CaM, contained in the resulting supernatant, were
separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. I. sodium dodecyl sulfate-polyacrylamide gel electrophoresis; B, fluorogram of the gel
electrophoresis. The reaction was carried out in the presence of: lane I, Ca2* (0.5 mvi); lane 2, Ca2* plus Mg2* (0.5 m.Mplus 5 mivi); lane 3. Mg2* (5 mM); or lane 4.
EDTA (5 mivi). Lane 5, control performed in the presence of Ca1* plus Mg2* (0.5 HIMplus 5 m\i) but without |3H]TAZ; lane 6, stock CaM solution (=60 jig); lane 7,
molecular mass markers:bovine albumin, 66 kDa; egg albumin, 45 kDa; glyceraldehyde-3-phosphate dehydrogenase, 36 kDa; trypsinogen, 24 kDa: trypsin inhibitor,
20 kDa; calmodulin, 17 kDa.
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Fig. 8. Effect of Tx and trifluoperazine on the CaM-stimulated (Ca2* + Mg2*)-
ATPase of RBC plasma membranes. The activity of (Ca2* + Mg2*)-ATPase was
determined in the absence or presence of Tx or trifluoperazine (1-50 /JM)and 10
<jg of CaM, as described in "Materials and Methods." , CaM-stimulated
ATPase; , basal ATPase. O, presence of Tx, â€¢,presence of trifluoperazine.
The points represent the mean values obtained from three experiments.
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Fig. 9. Reversal of the inhibitory effect of Tx on the ATPase by an excess of
CaM. The ATPase activity was determined in the presence of 10 or 90 Â»jgof CaM
and various concentrations of Tx, as described in Fig. 8. O, presence of 10 Â¡i%of
CaM; D, presence of 90 ng CaM. The points represent the mean values obtained
from two experiments.
its absence. Furthermore, it was reported that CaM contains
four Mg:+ binding sites and that, at high concentrations of both
cations, a CaM-Ca4-Mg4 species is formed (33). Probably these
Ca2*-dependent Mg2*-regulated conformers of CaM are re
sponsible for the different effects of Mg2* on the interaction of
CaM with its ligands, such as receptor proteins (30, 31), and
with CaM antagonists (32).
The results described here indicate that CaM conformations
induced by Ca2* in the absence of Mg2* appear to be more
favorable for Tx binding. The free Ca2* concentration for
maximal binding of the drug is about 10~5M, which corresponds
to a concentration of Ca2* which activates CaM in the cell (34).
This activation involves exposure of an hydrophobic domain of
the CaM molecule, which serves as the acceptor site either for
the CaM-modulated enzymes or for the CaM antagonist drugs
(21, 35, 36). Hydrophobic compounds, such as phenothiazines,
R-24571, compound 48/80, and others, have been described as
good antagonists of the CaM modulatory effects. However, it
has been reported that anticalmodulin properties are deter
mined not only by hydrophobic interactions but also by electro
static interactions (37, 38). Prozialeck and Weiss (37) noticed
that all of the most potent CaM inhibitors have several common
structural characteristics, namely a large hydrophobic region
composed of aromatic rings and an amino side chain group,
which accounts for those molecular forces, respectively. The
triphenylthylene antiestrogen Tx has a structure with these
hydrophobic and hydrophilic portions (19, 20), so it can easily
interact with CaM. This interaction is demonstrated in the
fluorogram reported here, which clearly shows that, even at
very low Tx concentrations (nanomolar range), the formation
of the cation-dependent CaM-Tx adduct occurs (Fig. 7).
Two distinct classes of cation-dependent binding sites were
found; one of them saturates in the nanomolar range of Tx
concentration (Fig. 3), whereas the other one saturates in the
micromolar range (Fig. 4). Under these conditions, the Tx
binding appears to be specific, in the sense that both labeled
and unlabeled Tx or trifluoperazine compete for the same
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binding sites of CaM. Furthermore, in the micromolar range
of Tx concentrations, we observed positive cooperativity for the
Tx binding to CaM (Figs. 4, 5, and 6). These results are
consistent with previous studies on the interaction of other
hydrophobic CaM antagonists such as trifluoperazine (39),
felodipine (40, 41), and [3H]norchlorpromazine isothiocyanate
with CaM (42).
Although a significant Ca2+-dependent binding of Tx to CaM
occurs at nanomolar concentrations, the inhibition of the (Ca2+
+ Mg2+)-ATPase is only observed in the micromolar range, in
agreement with previous results obtained using other CaM
antagonists (43, 44). These observations probably are related
to the large partitioning of the drugs within the lipid phase of
the membranes (45), so that the real concentration of the drug
at its target molecule (CaM) is less than that expected from the
added concentration.
The plasma membrane (Ca2+ + Mg2+)-ATPase is not the only
CaM-regulated enzyme which is inhibited by Tx. It has been
demonstrated that Tx is a CaM antagonist in the activation of
the cAMP phosphodiesterase, a key enzyme for the metabolism
of cyclic nucleotides (16, 18). Furthermore, protein kinase C,
which is a crucial enzyme in tumor promotion, has been re
ported to be inhibited by Tx (46, 47), suggesting that the
antiproliferative effects of the drug may involve several com
ponents of the second messenger system. Indeed, the cellular
effects of Tx cannot be explained solely by estrogenic blockage,
since some estrogen receptor-negative breast cancer cells re
spond to Tx (48). High affinity antiestrogen binding sites,
distinct from the estrogen receptors, have been reported by
several investigators (8-13), but their nature is not known. In
this work, the results indicate that CaM may be part of these
antiestrogen binding sites, which have an affinity for Tx (6 HM)
higher than that exhibited by the estrogen receptors (Â«80HM)
(1). It has been suggested that CaM appears to be involved in
the estrogen action by stimulating tyrosine phosphorylation of
the estrogen receptor (49), which is converted from a nonbind-
ing to a hormone-binding state (50). Therefore, CaM antago
nism may be the primary event responsible for the antiestrogen
cell growth inhibition, even in the case of estrogen-reversible
action of antiestrogens. Recently, Musgrove et al. (51) also
reported that there is an indistinguishable mechanism for the
action of pure estrogen antagonists, nonesteroidal antiestro
gens, and calmodulin antagonists on breast cancer cell prolif
eration.
On the other hand, the Ca2+-dependent binding sites of CaM,
which we observed to bind Tx with low affinity (A"d,9 /UM),
appear to be ineffective at the levels of Tx found in the cytosol
of breast tumor cells (=1 /Â¿M)(52) and in human blood serum
(0.6 /UM)(53). Great divergence exists among the values re
ported for blood levels of Tx (0.5 nM to 0.5 Â¿Â¿M)(3, 53-56),
probably due to the efficiency of the methods used for extraction
and detection of Tx and its metabolites. Since Tx is a lipophilic
drug, it is trapped by cell membranes, so that the total amount
of Tx should be higher than that measured in the fluid fraction
(53-56), in agreement with the Tx concentrations (15 ÃŸM)
required to inhibit CaM stimulation of the CaM-modulated
enzyme tested in Fig. 8.
The results indicate that CaM inactivation by Tx involves Tx
binding to the high affinity Ca2+-dependent Tx binding sites of
CaM, although we cannot rule out the possibility that inhibition
of some CaM-modulated processes also requires the involve
ment of the Ca2+-dependent and cooperative class of CaM-
binding sites which bind Tx with low affinity.
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